SPHINGOLIPIDS AS SIGNALS FOR TUMOR NECROSIS FACTOR-A
鞘脂作为肿瘤坏死因子 A 的信号
基本信息
- 批准号:3201744
- 负责人:
- 金额:$ 15.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1992
- 资助国家:美国
- 起止时间:1992-08-01 至 1995-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The general goal of this grant proposal is to define a signal transduction
pathway for tumor necrosis factor (TNF)-alpha. This cytokine is a
principal host defense against foreign antigen and may serve a variety of
physiologic regulatory functions. Although a number of reports have
suggested a role for one of the known signalling systems, no coherent
picture has emerged for a second messenger pathway that may account for the
entirety of the pleiotropic effects of TNF-alpha. This proposal is based
on the recent observation that sphingomyelin degradation to ceramide is an
early event in TNF-alpha action in human promyelocytic leukemia (HL-60)
cells and that ceramide may substitute for TNF-alpha in monocytic
differentiation. During the past few years, this laboratory has described
a new metabolic pathway involving sphingomyelin and its derivatives. This
pathway is initiated by hydrolysis of plasma membrane sphingomyelin to
ceramide by the action of a sphingomyelinase. Subsequently, ceramide may
be de-acylated to sphingosine, an inhibitor of protein kinase C, or
phosphorylated to ceramide 1-phosphate, a compound newly discovered in this
laboratory. Because of apparent similarities between this metabolic
pathway and the phosphoinositide pathway, it was postulated that ceramide
may serve second messenger function. Indeed, a cell-permeable ceramide
analog induced selective phosphorylation of the epidermal growth factor
receptor on threonine 669. Based on this observation, this laboratory has
recently characterized a novel kinase that mediates this action of
ceramide, termed ceramide-activated protein kinase, in membranes derived
from HL-60 and A431 human epidermoid carcinoma cells. Elevation of
ceramide levels by TNF-alpha also resulted in enhanced kinase activity in
membranes derived from stimulated cells. The specific aims of this grant
are to: (1) demonstrate that this sphingomyelin pathway is tightly coupled
to activation of the TNF receptor both in intact cells and in vitro: (2)
show that this pathway is sufficient to mediate TNF-alpha-induced protein
phosphorylation; and (3) generalize this pathway to various models of TNF-
alpha action and in particular determine how it might relate to TNF-induced
cytotoxicity and cytostasis. Hopefully, these studies will provide
fundamental insights into the mechanism of TNF-alpha action and allow for
eventual pharmacologic manipulation of this system.
这项拨款提案的总体目标是定义一种信号转导
肿瘤坏死因子(TNF)-α的途径。 这种细胞因子是一种
主要宿主防御外来抗原,可用于多种
生理调节功能。 虽然有一些报告
提出了一个已知的信号系统的作用,没有连贯的
第二信使途径的图像已经出现,这可能解释了
TNF-α的多效性的全部。 该提案基于
根据最近的观察,鞘磷脂降解为神经酰胺是一种
人早幼粒细胞白血病(HL-60)中TNF-α作用的早期事件
神经酰胺可以替代单核细胞中的TNF-α,
分化 在过去的几年里,这个实验室已经描述了
涉及鞘磷脂及其衍生物的新代谢途径。 这
途径由质膜鞘磷脂水解启动,
神经酰胺通过鞘磷脂酶的作用。 随后,神经酰胺可
去酰化为鞘氨醇,一种蛋白激酶C的抑制剂,或
磷酸化为神经酰胺1-磷酸,这是一种新发现的化合物,
实验室 由于这种代谢和
途径和磷酸肌醇途径,假设神经酰胺
可以作为第二信使。 事实上,一种可渗透细胞的神经酰胺
类似物诱导的表皮生长因子的选择性磷酸化
第669章. 根据这一观察,该实验室
最近发现了一种新的激酶,它介导了
神经酰胺,称为神经酰胺活化蛋白激酶,在膜衍生
HL-60和A431人表皮样癌细胞。 标高
神经酰胺水平的TNF-α也导致增强的激酶活性,
膜来源于刺激的细胞。 该补助金的具体目的
目的是:(1)证明该鞘磷脂途径是紧密偶联的,
TNF受体在完整细胞和体外的活化:(2)
显示该途径足以介导TNF-α诱导蛋白
磷酸化;和(3)将该途径推广到TNF-α的各种模型。
α作用,特别是确定它如何与TNF诱导的
细胞毒性和细胞抑制。 希望这些研究能提供
对TNF-α作用机制的基本见解,并允许
最终对该系统进行药理学操作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard N Kolesnick其他文献
Richard N Kolesnick的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard N Kolesnick', 18)}}的其他基金
Ceramide-Rich Platforms Functionalize Gemcitabine Uptake
富含神经酰胺的平台可功能化吉西他滨的摄取
- 批准号:
10323269 - 财政年份:2021
- 资助金额:
$ 15.24万 - 项目类别:
Ceramide-Rich Platforms Functionalize Gemcitabine Uptake
富含神经酰胺的平台可功能化吉西他滨的摄取
- 批准号:
10543438 - 财政年份:2021
- 资助金额:
$ 15.24万 - 项目类别:
Patient-derived organoids reveal rectal cancers develop radiosensitivity
患者来源的类器官揭示直肠癌产生放射敏感性
- 批准号:
10343663 - 财政年份:2021
- 资助金额:
$ 15.24万 - 项目类别:
Dissecting anti-ceramide scFv vascular mitigation of the Radiation GI Syndrome
剖析抗神经酰胺 scFv 血管缓解辐射胃肠道综合症的作用
- 批准号:
9981619 - 财政年份:2017
- 资助金额:
$ 15.24万 - 项目类别:
Dissecting anti-ceramide scFv vascular mitigation of the Radiation GI Syndrome
剖析抗神经酰胺 scFv 血管缓解辐射胃肠道综合症的作用
- 批准号:
9385453 - 财政年份:2017
- 资助金额:
$ 15.24万 - 项目类别:
Dissecting anti-ceramide scFv vascular mitigation of the Radiation GI Syndrome
剖析抗神经酰胺 scFv 血管缓解辐射胃肠道综合症的作用
- 批准号:
10213610 - 财政年份:2017
- 资助金额:
$ 15.24万 - 项目类别:
C16-Ceramide Nano-Liposomes Reverse Multi-Drug Resistance
C16-神经酰胺纳米脂质体逆转多药耐药性
- 批准号:
9921301 - 财政年份:2016
- 资助金额:
$ 15.24万 - 项目类别:
Sphingolipid-Based Anti-Angiogenic Chemosensitization
基于鞘脂的抗血管生成化学增敏
- 批准号:
9274265 - 财政年份:2016
- 资助金额:
$ 15.24万 - 项目类别:
Sphingolipid-Based Anti-Angiogenic Chemosensitization
基于鞘脂的抗血管生成化学增敏
- 批准号:
9101093 - 财政年份:2016
- 资助金额:
$ 15.24万 - 项目类别:
C16-Ceramide Nano-Liposomes Reverse Multi-Drug Resistance
C16-神经酰胺纳米脂质体逆转多药耐药性
- 批准号:
9106835 - 财政年份:2016
- 资助金额:
$ 15.24万 - 项目类别:
相似海外基金
Ceramides as Novel Mediators of Tubular Metabolic Dysfunction Driving Kidney Injury
神经酰胺作为肾小管代谢功能障碍驱动肾损伤的新型调节剂
- 批准号:
10677394 - 财政年份:2023
- 资助金额:
$ 15.24万 - 项目类别:
The Role of Glycosyl Ceramides in Heart Failure and Recovery
糖基神经酰胺在心力衰竭和恢复中的作用
- 批准号:
10644874 - 财政年份:2023
- 资助金额:
$ 15.24万 - 项目类别:
Fundamental Studies on the Regulation and Interaction of Ceramides in Cellular Senescence and Cell Death
神经酰胺在细胞衰老和细胞死亡中的调控和相互作用的基础研究
- 批准号:
2314338 - 财政年份:2023
- 资助金额:
$ 15.24万 - 项目类别:
Standard Grant
Ceramides as Novel Mediators of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency-Induced Heart Failure.
神经酰胺作为极长链酰基辅酶A脱氢酶缺乏引起的心力衰竭的新型介体。
- 批准号:
10747561 - 财政年份:2023
- 资助金额:
$ 15.24万 - 项目类别:
Ceramides as novel drivers of metabolic dysfunction and colorectal cancer
神经酰胺作为代谢功能障碍和结直肠癌的新驱动因素
- 批准号:
10696086 - 财政年份:2022
- 资助金额:
$ 15.24万 - 项目类别:
The Role of Ceramides in the Pancreatic Beta Cell
神经酰胺在胰腺β细胞中的作用
- 批准号:
10592412 - 财政年份:2022
- 资助金额:
$ 15.24万 - 项目类别:
Ceramides as novel drivers of metabolic dysfunction and colorectal cancer
神经酰胺作为代谢功能障碍和结直肠癌的新驱动因素
- 批准号:
10505169 - 财政年份:2022
- 资助金额:
$ 15.24万 - 项目类别:
The Role of Ceramides in the Pancreatic Beta Cell
神经酰胺在胰腺β细胞中的作用
- 批准号:
10467400 - 财政年份:2022
- 资助金额:
$ 15.24万 - 项目类别:
Formation of biological barriers by diverse ceramides
多种神经酰胺形成生物屏障
- 批准号:
22H04986 - 财政年份:2022
- 资助金额:
$ 15.24万 - 项目类别:
Grant-in-Aid for Scientific Research (S)
Ceramides as a therapeutic target in experimental bronchopulmonary dysplasia
神经酰胺作为实验性支气管肺发育不良的治疗靶点
- 批准号:
442662 - 财政年份:2021
- 资助金额:
$ 15.24万 - 项目类别:
Operating Grants